Stock comparison
CorMedix
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
CRMD
CorMedix
Market cap
$626.05M
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | CRMD | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 63C | 65C | GMAB |
| Benjamin Graham | 38D | 64C | GMAB |
| Philip Fisher | 64C | 48D | CRMD |
| Peter Lynch | 64C | 25F | CRMD |
| Joel Greenblatt | 48D | 76B | GMAB |
| Charlie Munger | 67D | 68C | GMAB |
| Terry Smith | 71B | 71C | Tie |
Side-by-side metrics
| Metric | CRMD | GMAB |
|---|---|---|
| Market cap | $626.05M | $16.5B |
| P/E (TTM) | 3.3x | 6.2x |
| EV/EBIT | 3.7x | 12.0x |
| ROIC (TTM) | 27.59% | 43.78% |
| Gross margin | 85.83% | 93.88% |
| Net margin | 45.25% | 18.23% |
| Revenue CAGR 5y | 5.36% | -18.45% |
| EPS CAGR 5y | - | -23.48% |
| Debt / Equity | 0.3x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CRMD leads on
- Revenue CAGR 5y5.36%vs -18.45%+103%
- EV/EBIT3.7xvs 12.0x+69%
- Net margin45.25%vs 18.23%+60%
- P/E (TTM)3.3xvs 6.2x+46%
GMAB leads on
- Market cap$16.5Bvs $626.05M+96%
- Debt / Equity0.1xvs 0.3x+78%
- ROIC (TTM)43.78%vs 27.59%+37%
- Gross margin93.88%vs 85.83%+9%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.